Showing 1671-1680 of 1870 results for "".
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- Y.ora Vision and Eyexora Global Partner with SERI to Advance New MIGS Platform for Glaucomahttps://modernod.com/news/yora-vision-and-eyexora-global-partner-with-seri-to-advance-new-migs-platform-for-glaucoma/2484184/Y.ora Vision, a newly formed ophthalmic medical device company, announced the signing of a licensing agreement between the Singapore Eye Research Institute (SERI) and Eyexora Global to advance a next-generation minimally invasive surgical device for the treatment o
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen
- Reciprocal Tariffs Take Effect: What Eye Care Professionals Need to Knowhttps://modernod.com/news/reciprocal-tariffs-take-effect-august-7-what-eye-care-professionals-need-to-know/2482916/Eye care professionals and optical businesses across the US are bracing for major changes as the White House prepares to implement new reciprocal tariffs on imported goods from key trade partners beginning August 7, 2025. The tarriffs come following a temp
- Focus Vitamins Launches New Daily Eye Health Supplement: Focus Luteinhttps://modernod.com/news/focus-vitamins-launches-new-daily-eye-health-supplement-focus-lutein/2482758/Focus Vitamins, a physician-founded nutraceutical company under Covalent Medical, has announced the launch of 'Focus Lutein,' a daily eye health supplement designed to support long-term vision and defend against age-related changes.
- Virtual Vision Health Launches Visual Acuity Testing on Virtual Eye VR Platformhttps://modernod.com/news/virtual-vision-health-launches-visual-acuity-testing-on-virtual-eye-vr-platform/2482663/Virtual Vision Health announced the launch of visual acuity testing on its Virtual Eye VR platform. According to Virtual Vision, with patients needing regular visual acuity testing to monitor changes and maintain overall eye health, this feature ensures prov
- Stanford University Study Finds Ovarian Cancer Drug Can Affect the Eyeshttps://modernod.com/news/stanford-university-study-finds-ovarian-cancer-drug-can-affect-the-eyes/2482510/A study presented at the American Academy of Ophthalmology (AAO) meeting in Chicago found Mirvetuximab soravtansine (Elahere) is associated with corneal toxicity and related vision changes. Mirvetuximab is part of an emerging class of anti-cancer drugs called antibody-drug conjugates. A
- Robotic Cataract Surgery Using ForSight Robotics’ Oryom Platform Presented for the First Time at ASCRShttps://modernod.com/news/robotic-cataract-surgery-using-forsight-robotics-oryom-platform-presented-for-the-first-time-at-the-ascrs-annual-meeting/2482229/Robotic cataract surgery using ForSight Robotics’ Oryom platform on a porcine eye was presented at the 2024 ASCRS annual meeting by David F. Chang, MD, marking the debut of this technology at a professional conference. During
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st
- Amydis Launches Phase 2 Glaucoma Clinical Program Using Novel Retinal Tracer to Detect Amyloid Betahttps://modernod.com/news/amydis-launches-phase-2-glaucoma-clinical-program-using-novel-retinal-tracer-to-detect-amyloid-beta/2481939/Amydis announced it has launched a phase 2 clinical program for its novel retinal tracer, AMDX-2011P, to detect amyloid-beta in glaucoma patients. "Multiple diagnostic tests detect structural and vascular changes in the retina associated with glaucoma while visual function tes